Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials

Nov 7, 2024Diabetology & metabolic syndrome

Survodutide, a drug that activates glucagon and GLP-1 receptors, and its effects on weight loss: a combined analysis of clinical trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Participants experienced a significant weight reduction of 8.33 kg following Survodutide injections.

Significant decreases in body mass index (BMI) and waist circumference were also observed, with reductions of 4.03 kg/m and 6.33 cm, respectively.
Longer treatment durations (over 16 weeks) and higher doses (over 2 mg/week) are associated with greater reductions in weight and waist circumference.
The findings are based on data from 18 treatment arms involving 1029 participants.

AI simplified

BACKGROUND: Considering the increasing prevalence of obesity/overweight, its treatment or prevention with new interventions can greatly help health and reduce its adverse effects in people. One of these new interventions is investigating the effect of Survodutide as a dual agonist of glucagon and GLP-1 receptors, which seems to be able to influence weight loss processes in different ways. In this study, we investigated the effect of injectable Survodutide on weight loss.

METHODS: In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024. The pooled weighted mean difference and 95% confidence intervals were computed using the random-effects model.

RESULTS: The Findings from 18 treatment arms with 1029 participants indicated significant reductions in weight (WMD: -8.33 kg; 95% CI: -10.80, -5.86; I = 99.6%), body mass index (BMI) (WMD:-4.03 kg/m; 95% CI: -4.86, -3.20; I2 = 72.7%), and waist circumferences (WC) (WMD: -6.33 cm; 95% CI: -8.85 to -3.81; I = 99.5%) following the Survodutide injection compared to the control group. Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis. 2 2 2

CONCLUSIONS: The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.

Key numbers

-8.33 kg

Weight Reduction

Mean weight difference compared to control groups.

-4.03 kg/m

Reduction

Mean difference compared to control groups.

-6.33 cm

Reduction

Mean difference compared to control groups.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief